Curia

The countdown to #DCAT2025! Partnering with Curia means your pipeline is in expert hands. We're hard at work advancing your projects — from Curiosity to Cure! From Small Molecules to Generic APIs, Biologics, Sterile Fill-Finish, and Analytical Services — we’re your trusted ally every step of the way https://ow.ly/FRIG50Vgpxj #DCAT2025

#Breaking: Curia today announced it has refinanced its secured credit facilities. The transaction provides Curia with incremental capital and extends the maturities of its secured credit facilities, positioning the business for continued growth, allowing the company to capitalize on the attractive market opportunities in the drug development and manufacturing markets, and advancing its mission of partnering with biopharmaceutical customers to bring life-changing therapies to market. Curia's growth initiatives include significant investment expanding capabilities at its facilities in Rensselaer, New York, Albuquerque, New Mexico and Glasgow, UK. >>> Learn more at: https://lnkd.in/enUqP_pD

At Curia, we are proud to support International Women’s Day. We continue to #AccelerateAction toward women’s advancement and gender equality through our DE&I initiatives and support for women in STEM. In celebration of #IWD2025, Curia team members from all over the world shared what it means to accelerate action and emphasized the importance of urgent action to drive meaningful progress. #Internationalwomensday

Curia has a strong track record of getting APIs approved around the world, thanks to our expertise in navigating complex regulatory markets. Most recently, China approved one of our portfolio APIs, Betamethasone Dipropionate Micronized. This is yet another example of our commitment to delivering high-quality APIs and ensuring regulatory excellence on a global scale. Check out our API Catalog: https://ow.ly/vUBG50Vb39A #APIManufacturing #RegulatoryExcellence #CDMO

We’re thrilled to be exhibiting at Bioprocess International West! Stop by booth 816 to chat with our experts about manufacturing for mRNA and protein therapeutics. Let’s talk about how we can take your project from Curiosity to Cure! See you there! https://ow.ly/azhu50V6776 #Bioprocessing #Curia

At Curia, we are at the forefront of advancing novel conjugates, helping to accelerate the development of life-changing therapies through our cutting-edge technology, expertise, and commitment to quality. Together, we can unlock the potential of novel conjugates to create better, more targeted treatments for patients worldwide. Schedule time to meet with us, from Curiosity to Cure-Curia! https://ow.ly/3uA450V9jRE

#CuriaForRareDiseases: With over 6,000 identified rare diseases, millions of people face challenges in diagnosis and treatment. 1 in 5 cancers is rare, and 70% of rare diseases begin in childhood- yet treatment options remain limited. At Curia, we are dedicated to advancing solutions for rare diseases through API innovation, including offering Ganaxolone API for regulatory purposes. #Ganaxolone represents one of the many ways we’re supporting the development of therapies that can make a real difference in the lives of those affected. Because behind every rare disease statistic is a person, a family, and a story worth fighting for. Discover how Curia’s API capabilities, including Ganaxolone, are helping advance the treatment of rare diseases: https://ow.ly/rPs150V8oEB #APIInnovation #RareDiseaseResearch #Ganaxolone #FromCuriosityToCure

Congratulations to Michelle Lovatt on this incredible achievement! After years of hard work, dedication and perseverance, Michelle Lovatt, Senior Quality Specialist, is now eligible to become a Qualified Person (QP) at our site in Glasgow, Scotland. For Michelle, becoming a QP is more than a title- it’s a commitment to ensuring the highest standards of quality and compliance in pharmaceuticals. She’s driven by a passion for safeguarding public health and persevered through challenges by staying focused on continuous learning, expert support and a strong work-life balance. At Curia, QPs play a critical role in delivering safe, high-quality medicines to patients. Their expertise ensures that every product meets the highest standards before reaching those who need them most. To those aspiring to follow in her footsteps, Michelle’s advice is clear: Be patient, stay committed and always prioritize quality. Join us in celebrating Michelle’s remarkable journey! #Curiaway #CuriaProud #QualityExcellence #FromCuriosityToCure #WomenInPharm

We’re live from CHDI’s 20th Annual Huntington’s Disease Therapeutics Conference! Our scientists are sharing exciting research on Huntington’s disease, focusing on MMR-targeted antibody discovery and protein production, and DNA MMR pathway target analysis to advance HD therapeutics. Here’s what we’re presenting: ? Available Huntingtin Variants & Select Anti-HTT Antibodies ? Leveraging the Immunologic Diversity of the PentaMice? Platform and the Shared Component Features of Mismatch Repair Proteins for Efficient MMR-Targeted Antibody Discovery ? Protein production and characterization of exonuclease 1 (Exo1) in an exonuclease activity assay ? Protein production and characterization of FAN1 in an endonuclease activity assay ? Protein production and characterization of LIG1 in a ligation activity assay Let’s connect! Have questions or want to learn more? Reach out to Val Graziano ([email protected])

Exciting news! Curia’s leadership team is heading to DCAT Week 2025! Meet our CEO, Philip Macnabb , along with Steve Lichter, President of Small Molecules, and Scott Wagner, President of Drug Product. Don’t miss the chance to connect and explore how we can support your next project! ?? Schedule a meeting and let’s make great things happen! See you in NYC! https://ow.ly/oz9a50V6XJy #DCAT2025